Saturday 17 October 2026
Export ADPT’s income statement to Excel — free account
Adaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024. In the quarter to June 2026, revenue grew 21.5%, EPS fell 47.1% and free cash flow grew 42.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
24.02
1.56
−6.10%
Follow ADPT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
11.13 | 7.31 | 8.90 | 9.02 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(535.76) | (226.34) | 1,199.01 | (319.96) | |
P/B ratio |
22.76 | 9.63 | 10.95 | 11.16 | |
Price to Tangible BV |
111.31 | 20.76 | 23.62 | 27.43 | |
EV/Sales |
11.10 | 7.31 | 8.87 | 9.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(162.76) | (79.84) | (53.40) | (37.77) | |
EV/FCF |
(142.28) | (73.09) | (50.17) | (36.33) | |
Quick Ratio |
4.49 | 3.06 | 3.08 | 3.09 | |
Current Ratio |
4.79 | 3.35 | 3.34 | 3.38 | |
Net Debt/EBITDA |
0.77 | 14.08 | 25.60 | (15.01) | |
Debt/Assets |
52.27% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
2.22 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.54 | 0.58 | 0.53 | 0.48 | |
Operating CF/Net income |
0.16 | 0.48 | (0.15) | (0.75) | |
Capex/Depreciation |
(0.33) | (0.22) | (0.16) | (0.11) | |
Interest Coverage |
(5.85) | (6.65) | (4.32) | 3.46 | |
Research and Development Expense of Revenue |
26.77% | 33.33% | 30.36% | 25.19% | |
Selling, General and Administrative Expense of Revenue |
66.50% | 66.78% | 61.44% | 44.09% | |
Intangible Assets out of Total Assets |
0.19 | 0.24 | 0.24 | 0.25 | |
Share Based Compensation of Revenue |
15.54% | 16.83% | 17.75% | 14.11% | |
Graham Net Nets |
(0.02) | 0.00 | 0.01 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.91%) | (2.38%) | (2.46%) | (3.61%) | |
Free Cash Flow Yield |
(0.70%) | (1.37%) | (1.99%) | (2.76%) | |
Revenue per Share |
0.45 | 0.46 | 0.47 | 0.62 | |
Operating CF per Share |
(0.04) | (0.06) | 0.01 | (0.05) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.07) | 0.01 | (0.05) | |
Cash per Share |
2.15 | 1.40 | 1.50 | 1.40 | |
Shareholders Equity per Share |
0.94 | 1.44 | 1.48 | 1.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.94 | 1.44 | 1.48 | 1.34 | |
Free Cash Flow |
(7.58) | (10.33) | 1.42 | (7.54) | |
Working Capital |
332.85 | 204.80 | 210.27 | 198.07 | |
Capital Expenditures |
(1.18) | (0.80) | (0.64) | (0.41) | |
Net Current Asset Value |
(69.45) | 10.11 | 12.45 | (4.92) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
46.90 | 45.95 | 46.05 | 42.82 | |
Average Payables |
6.07 | 7.99 | 6.87 | 8.81 | |
Average Inventory |
9.45 | 9.95 | 9.13 | 10.94 | |
Average Assets |
568.66 | 508.40 | 526.06 | 524.56 | |
Average Common Equity |
165.10 | 207.23 | 213.74 | 213.91 |
Columns are period end dates